Table 4.
Drug level comparison
| Therapeutic drug level (n = 203) | Non-therapeutic drug level (n = 147) | p | |
|---|---|---|---|
| Antifungal medication | |||
| Voriconazole | 134 (66) | 116 (79) | <0.01 |
| Posaconazole | 69 (34) | 31 (21) | |
| Timing of level | |||
| Pre-steady-state | 72 (35) | 54 (37) | 0.82 |
| Steady-state | 131 (65) | 93 (63) | |
| Male | 98 (48) | 84 (57) | 0.11 |
| Weight (kg) (median [IQR]) | 71.0 (60.3–83.0) | 76.2 (59.1–88.3)a | 0.13 |
| Age (year) (median [IQR]) | 49 (36–61) | 47 (33–60) | 0.15 |
| Race and ethnicity | <0.01 | ||
| Caucasian | 135 (67) | 89 (61) | |
| African American | 20 (10) | 6 (4) | |
| American India or Alaskan native | 4 (2) | 6 (4) | |
| Asian | 6 (3) | 0 | |
| Hispanic | 22 (11) | 17 (12) | |
| Unknown | 16 (8) | 29 (20) | |
| Critically Ill | 88 (43) | 63 (43) | 1.00 |
| Transplant status | |||
| Solid organ recipients | 32 (16) | 21 (14) | 0.76 |
| Bone marrow recipients | 55 (27) | 40 (27) | 1.00 |
| Comorbidities | |||
| Cystic fibrosis | 18 (9) | 12 (8) | 0.85 |
| Gastrointestinal | 46 (23) | 25 (17) | 0.23 |
| Type of infection | |||
| Prophylaxis | 15 (7) | 7 (5) | 0.38 |
| Possible | 33 (16) | 32 (22) | |
| Probable | 58 (29) | 46 (31) | |
| Proven | 97 (48) | 62 (42) | |
| Organism (n = 245) | |||
| Candida spp. | 29 (20) | 38 (37) | <0.01 |
| Aspergillus spp. | 48 (33) | 34 (34) | |
| Mucor | 31 (21) | 7 (7) | |
| Scedosporium spp. | 18 (12) | 13 (13) | |
| Cryptococcus | 7 (5) | 0 | |
| Other | 13 (9) | 9 (9) | |
Data are presented as n (%) or median (interquartile range)
IQR interquartile range
an = 146 (weight unavailable for one drug level)